


Tivozanib TIVO-3

### PRELIMINARY SCORE

**CURATIVE**



**NON-CURATIVE**



### ADJUSTMENTS

**Quality of life**



**Serious and disabling adverse effects**



**Other adjustments**



Tivozanib TIVO-3

### FINAL SCORE

**CURATIVE**



Overall Survival / Disease-Free Survival / Pathological Complete Response

**NON-CURATIVE**



Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

**INFORMATION**

Tumour type: Genitourinary Cancers  
 Therapeutic Indication: Adult patients with relapsed or refractory advanced RCC following ≥2 prior systemic therapies  
 Experimental Arm: Tivozanib  
 Control Arm: Sorafenib

